<DOC>
	<DOCNO>NCT00553202</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy donor stem cell transplant use stem cell closely match patient 's stem cell , help stop growth cancer cell . It also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving antithymocyte globulin transplant cyclosporine , tacrolimus , methotrexate transplant may stop happen . PURPOSE : Natural Killer ( NK ) cell donor 's bone marrow may important fight leukemia . Bone marrow donor select base type NK cell , specifically killer immunoglobulin receptor ( KIR ) type . This study provide information KIR type potential donor , use select bone marrow donor . This phase II trial unrelated donor stem cell transplant patient high risk AML ( monosomy 7 , -5/5q- , high FLT3-ITD AR , refractory relapse AML ) KIR type patient potential donor available treat transplant physician time donor selection .</brief_summary>
	<brief_title>Donor Stem Cell Transplant Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7 , -5/5q- , High FLT3-ITD AR , Refractory Relapsed Acute Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - To define relationship status donor NK-cell receptor patient outcomes killer immunoglobulin-like receptor-incompatible unrelated donor ( URD ) umbilical cord blood ( UCB ) hematopoietic cell transplantation ( HCT ) young patient acute myeloid leukemia monosomy 7 , -5/5q- , high FLT3 internal tandem duplication allelic ratio ( High-FLT3-ITD AR ) , refractory relapse acute myelogenous leukemia . - To correlate relationship factor affect NK receptor status clinical event . - To assess NK-cell development URD UCB HCT patient poor prognosis AML . - To evaluate NK-cell reconstitution receptor-acquisition pattern patient . OUTLINE : This multicenter study . - Preparative regimen : Patients receive 1 follow regimen : - Hematopoietic stem cell transplantation ( SCT ) : Patients receive busulfan IV every 6 hour day -9 -6 , high-dose cyclophosphamide IV 1 hour day -5 -2 , anti-thymocyte globulin IV twice daily 4 hour day -3 -1 , methylprednisolone IV day -3 -1 . - Umbilical cord blood ( UCB ) transplantation : Conditioning regimen , infusion procedure , post-transplant immunoprophylaxis patient UCB donor accord institutional guideline standard . - Allogeneic hematopoietic stem cell transplantation ( SCT ) umbilical cord blood ( UCB ) transplant : Patients undergo allogeneic SCT UCB transplant day 0 . - Graft-vs-host disease ( GVHD ) prophylaxis : Patients receive cyclosporine tacrolimus IV orally begin day -2 continue day 50 , follow taper week 24 . Patients also receive methotrexate IV day 1 , 3 , 6 , 11 . Blood sample collect periodically patient donor study natural killer cell support study objective . After completion study treatment , patient follow every 6 month 2 year annually 3 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Monosomy</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis one following : Patients primary refractory acute myeloid leukemia ( AML ) , define ≥ 5 % bone marrow blast two induction course chemotherapy Primary refractory AML , define ≥ 5 % bone marrow blast two induction course chemotherapy AML myelodysplastic syndrome 5/5q monosomy 7 without inv ( 16 ) /t ( 16 ; 16 ) ( 8 ; 21 ) cytogenetics NPM CEBPα mutation Relapsed AML ( ≥ 5 % bone marrow blast ) meet customary WHO criteria AML AML high FLT3 internal tandem duplication allelic ratio ( high FLT3ITD AR ) , define &gt; 0.4 All case therapyrelated AML ( therapyrelated AML consider high risk ) Patients AML , without inv ( 16 ) /t ( 16 ; 16 ) ( 8 ; 21 ) , monosomy 7 , 5/5q , NPM , CEPBα mutation , high FLT3ITD AR , evidence residual AML ( ≥ 0.1 % ) end Induction I ; minimal residual disease ( MRD ) perform , &gt; 15 % bone marrow blast morphology one induction course chemotherapy Any flowbased MRD eligible AAML05P1 patient AAML1031 , whereas patient AAML1031 must utilize central lab per AAML1031 protocol guideline No Fanconi anemia Recipients unrelated marrow cord blood eligible study PATIENT CHARACTERISTICS : Karnofsky performance status ( PS ) ( patient 16 year age ) Lansky PS ( patient 16 ) 50100 % Total bilirubin ≤ 2 mg/dL SGOT ( AST ) SGPT ( ALT ) ≤ 2.5 time upper limit normal DLCO ≥ 50 % OR normal chest xray pulse oximetry patient unable undergo pulmonary function test Shortening fraction ≥ 27 % ECHO Creatinine clearance radioisotope glomerular filtration rate least 60 mL/min OR creatinine adjust accord age HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Patients proven suspect bacterial sepsis , pneumonia , meningitis eligible provide appropriate therapeutic measure initiate control presume proven infection , systemic sign lifethreatening No evidence presence fungal infection within past 30 day PRIOR CONCURRENT THERAPY : Prior chemotherapy , radiotherapy antileukemic therapy allow provided patient meet 1 follow criterion : Received initial treatment relapse AML Patients primary induction failure relapse already receive initial therapy may go additional therapy prior receive protocol stipulate therapy AAML05P1 No treatment fungal infection within past 30 day Concurrent radiotherapy localize painful lesion allow No concurrent cancer chemotherapy immunomodulating agent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>